Guobang Pharma Temettü
Temettü kriter kontrolleri 2/6
Guobang Pharma is a dividend paying company with a current yield of 1.55% that is well covered by earnings.
Anahtar bilgiler
1.5%
Temettü verimi
0.9%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | 2.5% |
| Gelecekteki Temettü Verimi | 3.8% |
| Temettü Büyümesi | 14.4% |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | CN¥0.302 |
| Ödeme oranı | 24% |
Son temettü güncellemeleri
Güncelleme yok
Recent updates
Calculating The Fair Value Of Guobang Pharma Ltd. (SHSE:605507)
Aug 26
These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively
Jul 24Guobang Pharma Ltd. (SHSE:605507) Analysts Just Cut Their EPS Forecasts Substantially
May 21Fewer Investors Than Expected Jumping On Guobang Pharma Ltd. (SHSE:605507)
Apr 18We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt
Mar 25Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: 605507 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Büyüyen Temettü: 605507 has only been paying a dividend for 3 years, and since then payments have fallen.
Piyasaya Karşı Temettü Getirisi
| Guobang Pharma Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (605507) | 1.5% |
| Pazarın Alt %25'i (CN) | 0.6% |
| Pazarın En İyi %25'i (CN) | 2.2% |
| Sektör Ortalaması (Pharmaceuticals) | 1.7% |
| Analist tahmini (605507) (3 yıla kadar) | 3.8% |
Önemli Temettü: 605507's dividend (1.55%) is higher than the bottom 25% of dividend payers in the CN market (0.57%).
Yüksek Temettü: 605507's dividend (1.55%) is low compared to the top 25% of dividend payers in the CN market (2.22%).
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: With its low payout ratio (23.9%), 605507's dividend payments are well covered by earnings.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: With its high cash payout ratio (267.6%), 605507's dividend payments are not well covered by cash flows.